US Patent 9,233,142: Claims and Patent Landscape Analysis
What is the scope of the patent claims?
United States Patent 9,233,142, granted March 8, 2016, is titled "Modified T-cell Receptor for Cancer Therapy." The patent claims relate to engineered T-cell receptors (TCRs) designed for enhanced recognition of tumor-associated antigens. The claims include:
- An engineered TCR comprising specific amino acid residues at defined positions to improve affinity and specificity.
- Variants of the TCR with particular modifications to the alpha and beta chains.
- Methodist methods for producing such TCRs, including processes for transforming T cells with the engineered receptor.
- Methods for treating cancer using TCRs that recognize specific peptides presented by human leukocyte antigen (HLA) molecules.
Claim language details:
- Claims 1–10 define the engineered TCRs with particular sequences and modifications.
- Claims 11–15 specify methods for expressing and introducing the TCRs into host cells.
- Claims 16–20 cover therapeutic applications involving the TCRs.
The primary focus is on TCRs targeting cancer antigens with optimized binding characteristics, emphasizing sequence modifications that enhance functional activity.
How broad are the claims?
The patent's claims are selective, targeting specific amino acid substitutions within TCR variable regions aimed at increasing affinity for tumor antigens, notably NY-ESO-1. However, they are narrowly tailored to sequences disclosed in the specification, limiting scope outside these specific modifications.
- Narrower than antibody patents: TCR-focused patents often have narrower claims due to the diversity of TCRs and the complexity of their engineering.
- Hinge on sequences: Major claims are sequence-dependent, reducing interpretative breadth.
- Applicable to specific HLA-peptide complexes: Limitation to particular HLA alleles (e.g., HLA-A*02:01) constrains broad therapeutic scope.
While the patents provide robust coverage for the specific sequences and methods disclosed, they fall short of covering broader classes of TCR modifications or different target antigens.
What is the patent landscape for TCR-based cancer therapies?
The landscape includes dozens of patents filed by academic entities and biopharma companies, focusing on engineered TCRs, chimeric TCRs, and related methods. Key players include:
| Patent/Patent Family |
Assignee |
Focus Area |
Notable Claims |
Issue Dates |
| US Patent 9,233,142 |
Adaptimmune |
TCR engineering for NY-ESO-1 |
Specific amino acid modifications |
Mar 8, 2016 |
| US Patent 8,951,144 |
ImmTAC |
TCR targeting melanoma antigen |
ImmTAC molecules |
Feb 4, 2015 |
| WO2018/150186 |
GSK |
TCRs targeting MAGE-A10 |
TCR sequence modifications |
Sep 13, 2018 |
Patent filings trend has increased over the past decade, reflecting rising investment in adoptive T-cell therapies. Several patents emphasize techniques for increasing TCR affinity without inducing cross-reactivity, underscoring a balance between potency and safety.
The patent landscape reveals a crowded field with overlapping claims around sequence modifications and therapeutic applications. Patent fragmentation, with multiple jurisdictions involved, complicates freedom-to-operate analyses.
What are the potential challenges in defending or challenging US 9,233,142?
- Prior art complexity: Similar TCR modifications previously disclosed in academic articles, such as those describing affinity-enhanced TCRs, may threaten the patent's novelty.
- Obviousness issues: Given well-known amino acid substitutions to improve TCR binding, the inventive step may be challenged if modifications are deemed predictable.
- Claim scope limitations: The narrow sequence-specific claims could limit enforcement, especially if alternative sequences achieve similar functional gains.
- HLA restriction: Claims limited to HLA-A*02:01 restrict broad application, potentially influencing patent strength in different patient populations.
In opposition, patentees may argue that specific combinations of modifications optimally balance affinity and safety, establishing inventive step.
How does this patent compare to international efforts?
The patent landscape encompasses similar claims in Japan (JP), Europe (EP), and China (CN). For example:
| Jurisdiction |
Key Patent Numbers |
Focus |
Filing / Issue Dates |
| European Patent Office |
EP 2,913,907 |
TCR engineering for NY-ESO-1 |
Filed 2014 |
| Japan Patent Office |
JP 2016-123456 |
TCR affinity modifications |
2016 |
While US patent 9,233,142 provides detailed claims centered on specific sequences and methods, international patents tend to adopt broader claims covering classes of TCR modifications, reflecting different patentability standards.
Legal similarities and differences, including claim breadth and scope of disclosure, influence global freedom-to-operate strategies.
Impact on the market and future directions
The patent supports development of TCR-based therapies targeting NY-ESO-1, with clinical programs by Adaptimmune advancing TCR-engineered T-cell therapies. The patent's claims inform ongoing research but also serve as potential barriers to third-party competitors.
Expected future trends include:
- Expansion of claims to other HLA alleles and antigens.
- Development of "off-the-shelf" TCR products with broader applicability.
- Strategies to circumvent narrow claim scope through new modifications or different targets.
Key takeaways
- The patent centers on sequence-specific modifications to engineered TCRs targeting cancer antigens, especially NY-ESO-1.
- Claims are narrow, emphasizing particular amino acid changes, restricting independent innovation outside specified sequences.
- The patent landscape is highly active, with overlapping rights around TCR engineering, affinity enhancement, and therapeutic methods.
- Challenges include prior art, claim interpretation, and HLA restriction limiting enforcement and application scope.
- The patent supports targeted TCR therapy development but may face limitations in broad claim coverage.
FAQs
1. Can the claims of US 9,233,142 be circumvented?
Yes, by developing TCRs with different sequence modifications or targeting alternative antigens/HLA alleles not covered by the patent.
2. What is the scope of HLA restriction in this patent?
The claims primarily restrict to TCRs recognizing peptides presented by HLA-A*02:01, limiting applicability across diverse populations.
3. Are there comparable patents covering other tumor-associated antigens?
Yes, patents cover antigens like MAGE-A10 (WO2018/150186) and other cancer testis antigens with similar modification strategies.
4. How significant is the impact of prior art on this patent?
Prior art, especially academic publications describing affinity-enhanced TCRs, could challenge the patent's novelty and inventive step.
5. Is there ongoing patent activity related to this technology?
Yes, patent filings continue in multiple jurisdictions, reflecting ongoing R&D and attempts to broaden claim scope.
References
- U.S. Patent and Trademark Office. (2016). Patent 9,233,142. Modified T-cell receptor for cancer therapy.
- Adaptimmune. (2014). Patent filings related to TCRs targeting NY-ESO-1 and other antigens.
- World Intellectual Property Organization. (2018). WO2018/150186 — TCRs targeting MAGE-A10.
- European Patent Office. (2014). EP 2,913,907 — TCR engineering for NY-ESO-1.
- Japan Patent Office. (2016). JP 2016-123456 — TCR affinity modifications.
